Barinthus Biotherapeutics (NASDAQ:BRNS) Trading 6.2% Higher – Here’s Why

Barinthus Biotherapeutics plc (NASDAQ:BRNS) rose 6.2% during mid-day trading on Thursday . The company traded as high as $1.03 and last traded at $1.02. Approximately 19,171 shares traded hands during trading, a decline of 50% from the average daily volume of 38,688 shares. The stock had previously closed at $0.96.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their target price on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, January 13th.

Barinthus Biotherapeutics Stock Down 3.4 %

The company has a market cap of $39.63 million, a price-to-earnings ratio of -0.66 and a beta of -0.80. The firm has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.14.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. acquired a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics makes up 0.0% of Gilead Sciences Inc.’s portfolio, making the stock its 14th biggest position. Gilead Sciences Inc. owned about 1.54% of Barinthus Biotherapeutics at the end of the most recent quarter. 25.20% of the stock is currently owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.